New Role of Tumor Mutation Burden as a Predictor to Chemo/Targeted Therapy in Advanced Non-Small Cell Lung Cancer

培美曲塞 医学 肺癌 肿瘤科 内科学 队列 癌症 化疗 靶向治疗 顺铂
作者
Lin Chen,Xun Shi,Jun Zhao,Qiong He,Yang Shao,Xinmin Yu,Ying Jin
出处
期刊:Social Science Research Network [Social Science Electronic Publishing]
标识
DOI:10.2139/ssrn.3463249
摘要

Background: Accumulating evidence illustrates greater benefit of immunotherapy in tumors with high-TMB, whereas its impact on response to targeted therapy or chemotherapy is undefined.Methods: In this retrospective study, we investigated the correlation of tumor mutation burden (TMB) and progression-free survival (PFS) of NSCLC patients who received EGFR-TKIs or Pemetrexed/Platinum as first line therapy. TMB was evaluated by targeted next generation sequencing (tNGS). Patients were divided into low(L) / intermediate(I) / high(H) TMB groups by tertiles.Results: In EGFR-mutant cohort, TMB-L patients had an massively improved PFS compared to TMB-I/H patients(P=0.006) when treated with first generation of EGFR-TKIs. In EGFR/ALK wild-type cohort who received Pemetrexed/Platinum regimen, the ORR in TMB-L group was statistically superior than that of TMB-I/H groups (P=0.037), and patients with low TMB had a numerically, but not significantly prolonged PFS (P=0.22). No difference in PFS was observed between TMB-I and TMB-H groups in two treatment arms.Conclusions: Low nonsynonymous TMB indicated a favorable PFS for EGFR-TKIs and positive response to Pemetrexed/Platinum in certain cohorts with advanced NSCLC, which could potentially identify patients more suitable for targeted therapy or chemotherapy, rather than immunotherapy.Funding Statement: This work was supported by National Natural Science Foundation of China (Grant No.81702248) and Zhejiang medical and health science and technology project (Grant No.2018KY309).Declaration of Interests: The authors have declared no conflicts of interest.Ethics Approval Statement: Study protocols were approved by the Ethical Review Community of Zhejiang Cancer Hospital. The requirement of informed consent was waived by the committee as it was a retrospective research.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
光亮不平发布了新的文献求助10
刚刚
小慈爱鸡完成签到 ,获得积分10
1秒前
1秒前
改论文不看剧应助xsc采纳,获得10
2秒前
3秒前
xiaofenzi发布了新的文献求助10
3秒前
小曹完成签到,获得积分10
3秒前
小豆豆应助xcxc采纳,获得30
4秒前
眼睛大雨筠应助budingman采纳,获得30
4秒前
4秒前
友好的天奇完成签到 ,获得积分10
4秒前
酷酷凤灵发布了新的文献求助10
5秒前
研友_VZG7GZ应助典雅的幼菱采纳,获得10
5秒前
寒冷山雁完成签到,获得积分10
6秒前
6秒前
6秒前
典雅碧空应助高兴的土豆采纳,获得10
7秒前
诸天蓉发布了新的文献求助10
7秒前
7秒前
8秒前
小城故事发布了新的文献求助10
9秒前
嗨Honey发布了新的文献求助10
10秒前
三年半完成签到,获得积分10
10秒前
hugdoggy完成签到,获得积分10
10秒前
11秒前
Jenaloe完成签到,获得积分10
11秒前
光亮不平完成签到,获得积分10
11秒前
12秒前
12秒前
12秒前
12秒前
科研通AI2S应助科研通管家采纳,获得10
12秒前
ll应助科研通管家采纳,获得10
12秒前
所所应助酷酷凤灵采纳,获得30
12秒前
华仔应助科研通管家采纳,获得10
12秒前
12秒前
科研通AI2S应助科研通管家采纳,获得10
12秒前
Orange应助科研通管家采纳,获得10
13秒前
英俊的铭应助科研通管家采纳,获得10
13秒前
13秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance 500
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970008
求助须知:如何正确求助?哪些是违规求助? 3514711
关于积分的说明 11175563
捐赠科研通 3250077
什么是DOI,文献DOI怎么找? 1795198
邀请新用户注册赠送积分活动 875630
科研通“疑难数据库(出版商)”最低求助积分说明 804931